Clinical trial of MGCD 265 in patients with Axl-positive non-small cell lung cancer

Trial Profile

Clinical trial of MGCD 265 in patients with Axl-positive non-small cell lung cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MethylGene
  • Most Recent Events

    • 09 Mar 2016 In Sept 2015, results of this trial were presented at the World Conference on Lung Cancer 2015, as per Mirati Therapeutics media release.
    • 11 Sep 2015 According to a Mirati Therapeutics media release, the results from first non-small cell lung cancer patient with AXL gene amplification enrolled in the phase 1b expansion cohort will be presented at the Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer.
    • 11 Mar 2015 Status changed from not yet recruiting to recruiting, based on information in a Mirati Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top